<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	xmlns:media="http://search.yahoo.com/mrss/" >

<channel>
	<title>恒捷 &#8211; 元哲咨询</title>
	<atom:link href="https://www.yuanzhezixun.com/tag/hengjie/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.yuanzhezixun.com</link>
	<description>行业研究专家</description>
	<lastBuildDate>Tue, 22 Jun 2021 09:04:24 +0000</lastBuildDate>
	<language>zh-Hans</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	

<image>
	<url>https://www.yuanzhezixun.com/wp-content/uploads/2021/10/cropped-shcrilogo-c-45x45.jpg</url>
	<title>恒捷 &#8211; 元哲咨询</title>
	<link>https://www.yuanzhezixun.com</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>2021-2025年中国利奈唑胺市场研究报告(中文版含税价人民币12,000元)</title>
		<link>https://www.yuanzhezixun.com/2021-2025nianzhongguolinaizuoanshichangyanjiubaogao/</link>
		
		<dc:creator><![CDATA[Timlee]]></dc:creator>
		<pubDate>Tue, 22 Jun 2021 09:03:54 +0000</pubDate>
				<category><![CDATA[医/药/保健]]></category>
		<category><![CDATA[报告速递]]></category>
		<category><![CDATA[行业资讯]]></category>
		<category><![CDATA[CAP]]></category>
		<category><![CDATA[HAP]]></category>
		<category><![CDATA[MRSA]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[SSTI]]></category>
		<category><![CDATA[ZYVOX]]></category>
		<category><![CDATA[利奈唑胺]]></category>
		<category><![CDATA[华邦制药]]></category>
		<category><![CDATA[复杂性皮肤或皮肤软组织感染]]></category>
		<category><![CDATA[天礼]]></category>
		<category><![CDATA[恒捷]]></category>
		<category><![CDATA[恶唑烷酮]]></category>
		<category><![CDATA[抗生素]]></category>
		<category><![CDATA[斯沃]]></category>
		<category><![CDATA[正大天晴]]></category>
		<category><![CDATA[社区获得性肺炎]]></category>
		<category><![CDATA[耐万古霉素肠球菌(VRE)感染]]></category>
		<category><![CDATA[耐甲氧西林金黄色葡萄球菌]]></category>
		<category><![CDATA[菲康宁]]></category>
		<category><![CDATA[豪森药业]]></category>
		<category><![CDATA[辉瑞]]></category>
		<category><![CDATA[院内获得性肺炎]]></category>
		<category><![CDATA[革兰阳性(G+)球菌]]></category>
		<guid isPermaLink="false">http://www.yuanzhezixun.com/?p=24403</guid>

					<description><![CDATA[利奈唑胺是一种恶唑烷酮类抗生素，主要用于治疗革兰阳性(G+)球菌引起的感染。CRI元哲的调研数据显示，2020年中国市场的利奈唑胺销售额为6.95亿元人民币，2016-2020年中国市场的利奈唑胺销售额CAGR达到14.45%。CRI元哲预计在2021-2025年随着新冠疫情的缓解，中国市场利奈唑胺销售额将有恢复性的增长。<div class='yarpp yarpp-related yarpp-related-rss yarpp-related-none yarpp-template-list'>

没有相关文章
</div>
]]></description>
		
		
		
			</item>
	</channel>
</rss>
